Merck (NYSE:MRK) reported multiple positive Phase 3 results for KEYTRUDA-based combinations in renal cell carcinoma, bladder cancer, and ovarian cancer. The trials showed significant survival benefits ...
A combination of Merck’s Keytruda and Pfizer’s Padcev could offer a chemotherapy-free treatment alternative for patients with muscle-invasive bladder cancer, even those eligible for cisplatin ...
Commercial launch is on-track for ZUSDURI™, the first and only FDA-approved medication for adults with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC); net sales ...
Induction Yervoy (ipilimumab) plus Opdivo (nivolumab) followed by consolidative chemoradiotherapy demonstrated bladder ...
US pharma giant Pfizer has withdrawn its European application for a marketing authorization of Zumrad (sasanlimab) for the ...
Commercial launch is on-track for ZUSDURI, the first and only FDA-approved medication for adults with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC); net sales ...
Chief Commercial Officer David Lin reported, “ZUSDURI generated $1.8 million in net product revenue in Q3, and $14 million in Q4, bringing full year 2025 revenue to $15.8 million,” and detailed ...
Joining me today are Elizabeth A. Barrett, President and Chief Executive Officer; Mark P. Schoenberg, Chief Medical Officer; ...
News-Medical.Net on MSN
Seeing the unseen in bladder cancer surgery
Ten years ago, a discussion in Milan set a demanding project in motion. In a meeting between a biologist and a urologist, one ...
Patients with a common form of kidney cancer called clear cell renal cell carcinoma (ccRCC) who have a high risk of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results